Chemomab Therapeutics (CMMB) Operating Expenses (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Operating Expenses came in at $2.0 million in Q4 2025, down 38.56% YoY from $3.2 million in Q4 2024, and up 7.05% on a QoQ basis from $1.8 million in Q3 2025.
Chemomab Therapeutics (CMMB) Operating Expenses (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Operating Expenses data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Operating Expenses fell 38.56% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.6 million (down 35.09% YoY) and the FY2025 annual result came in at $9.6 million, down 35.09% from the prior year.
- Operating Expenses grew to $2.0 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $9.0 million in Q1 2023 to a low of $1.7 million in Q1 2021.
- A 5-year average of $4.5 million and a median of $3.8 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 213.13% — and 2023, when it plunged 55.47%.
- Tracing CMMB's Operating Expenses over 5 years: stood at $5.0 million in 2021, then surged by 72.01% to $8.6 million in 2022, then tumbled by 55.47% to $3.8 million in 2023, then fell by 16.5% to $3.2 million in 2024, then slumped by 38.56% to $2.0 million in 2025.
- The last three Operating Expenses figures came in at $2.0 million (Q4 2025), $1.8 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 3.49 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 8.20 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | 8.64 Mn |
| Sep 30, 2022 | 8.32 Mn |
| Jun 30, 2022 | 6.25 Mn |
| Mar 31, 2022 | 5.32 Mn |
| Dec 31, 2021 | 5.02 Mn |
| Sep 30, 2021 | 2.89 Mn |
| Jun 30, 2021 | 2.75 Mn |
| Mar 31, 2021 | 1.70 Mn |